Abstract

We developed anti-Akt1 single-chain antibodies (scFv) by panning a mouse phage-displayed scFv recombinant antibody library. Recombinant scFv that bound glutathione S-transferase (GST)-Akt1 were screened for their ability to inhibit Akt activity in vitro in a kinase reaction containing human recombinant Akt1 and an Akt/serum glucocorticoid-inducible kinase (SGK) substrate. Michaelis-Menten analysis of kinase inhibition by a selected scFv was consistent with scFv-mediated competition with enzyme's substrate for the catalytic site of Akt. To generate a membrane-permeable version of the anti-Akt1 scFv, the scFv gene was subcloned into a GST expression vector carrying a membrane-translocating sequence (MTS) from Kaposi fibroblast growth factor. A purified GST-anti-Akt1-MTS fusion protein accumulated intracellularly in 293T, BT-474, and PyVmT cells in a dose- and time-dependent fashion. Intracellular accumulation correlated temporally with inhibition of p-Ser(473) Akt and GSK-3alpha/beta phosphorylation, suggesting that Ser(473) is an Akt autophosphorylation site. Phosphorylated (activated) phosphoinositide-dependent kinase 1, mitogen-activated protein kinase, p38, and HER2 (erbB2) were not affected, supporting Akt kinase specificity for the inhibitory scFv. Exogenously expressed constitutively active Akt2 and Akt3 were also inhibited in vitro by the anti-Akt1 fusion protein. Furthermore, GST-anti-Akt1-MTS induced apoptosis in three cancer cell lines that express constitutively active Akt. Finally, systemic treatment with the anti-Akt scFv reduced tumor volume and neovascularization and increased apoptosis in PyVmT-expressing transgenic tumors implanted in mouse dorsal window chambers. Thus, GST-anti-Akt1-MTS is a novel cell-permeable inhibitor of Akt, which selectively inhibits Akt-mediated survival in intact cells both in vitro and in vivo.

Highlights

  • Antibodies and antibody-based reagents have been used for the treatment of cancer [1, 2]

  • More than 50 scFv clones interacted with glutathione S-transferase (GST)-Akt1 as determined by E-Tag ELISA

  • To screen for scFv-mediated inhibition of Akt1– MTS to its target (Akt) activity, we developed an in vitro kinase assay utilizing recombinant Akt1 (rAkt1) and a synthetic Akt/serum glucocorticoidinducible kinase (SGK) peptide

Read more

Summary

Introduction

Antibodies and antibody-based reagents have been used for the treatment of cancer [1, 2]. The humanized IgG1 trastuzamab (Herceptin) is an effective treatment for breast cancers that overexpress the HER2/neu (erbB2) proto-oncogene [3]. Mouse monoclonal antibodies can be chimerized by such approaches to prevent the production of human antimurine antibodies (HAMA) when administered to immune-competent humans [5]. An alternative strategy is to replace the antibody gene present in mouse B cells with human antibody genes. These modified B cells can be used to produce hybridoma cell lines that express fully humanized monoclonal antibodies that avoid cross-species immune response (i.e., HAMA) and, in addition, can trigger human host cell effector functions, such as complement fixation [6]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.